AB 1788: Public health: Valley Fever.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-08-28
Existing law requires the State Department of Public Health to establish a list of reportable diseases and conditions. Existing law requires, for each reportable disease and condition, the department to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made.
This bill would, until January 1, 2024, authorize the department, for the purpose of reports confirming a case of Valley Fever, to use laboratory criteria for diagnosis, with or without clinical criteria.
Existing law requires the State Department of Public Health to establish a list of reportable diseases and conditions. Existing law requires, for each reportable disease and condition, the department to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made.
This bill would, until January 1, 2024, authorize the department, for the purpose of reports confirming a case of Valley Fever, to use laboratory criteria for diagnosis, with or without clinical criteria.
Existing law requires the State Department of Public Health to establish a list of reportable diseases and conditions. Existing law requires, for each reportable disease and condition, the department to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made.
This bill would would, until January 1, 2024, authorize the department, for the purpose of reports confirming a case of Valley Fever, to use a laboratory criteria for diagnosis, with or without clinical criteria.
Existing law requires the Department of Public Health to establish a list of reportable diseases and conditions. Existing law requires, for each reportable disease and condition, the department to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made.
This bill would authorize the department, for the purpose of reports confirming a case of Valley Fever, to use a laboratory criteria for diagnosis, with or without a clinical criteria.
Existing law requires the Department of Public Health to establish a list of reportable diseases and conditions. Existing law requires, for each reportable disease and condition, the department to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made.
This bill would authorize the department, for the purpose of reports confirming a case of Valley Fever, to use a laboratory criteria for diagnosis, with or without a clinical criteria.
(a)The department may, for the purpose of reports confirming a case of coccidioidomycosis, also known as Valley Fever, use laboratory criteria for diagnosis, with or without clinical criteria.
(b)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
(a)The department may, for the purpose of reports confirming a case of coccidioidomycosis, also known as Valley Fever, use laboratory criteria for diagnosis, with or without clinical criteria.
(b)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
(a)The department may, for the purpose of reports confirming a case of coccidioidomycosis, also known as Valley Fever, use a laboratory criteria for diagnosis, with or without clinical criteria.
(b)This section shall remain in effect only until January 1, 2024, and as of that date is repealed.
The department may, for the purpose of reports confirming a case of coccidioidomycosis, also known as Valley Fever, use a laboratory criteria for diagnosis, with or without a clinical criteria.
The department may, for the purpose of reports confirming a case of coccidioidomycosis, also known as Valley Fever, use a laboratory criteria for diagnosis, with or without a clinical criteria.
|
Date
|
Status
|
|---|---|
| Aug 28, 2018 | Chaptered by Secretary of State - Chapter 230, Statutes of 2018. |
| Aug 28, 2018 | Approved by the Governor. |
| Aug 16, 2018 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 13, 2018 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Jul 5, 2018 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 3 pursuant to Assembly Rule 77. |
| Jul 5, 2018 | Read third time. Passed. Ordered to the Assembly. |
| Jul 3, 2018 | Read second time. Ordered to third reading. |
| Jul 2, 2018 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Jun 18, 2018 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 14, 2018 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 13). |
| May 29, 2018 | In committee: Hearing postponed by committee. |
| May 3, 2018 | Referred to Com. on HEALTH. |
| Apr 19, 2018 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Apr 19, 2018 | Read third time. Passed. Ordered to the Senate. (Ayes 71. Noes 0.) |
| Apr 12, 2018 | Read second time. Ordered to Consent Calendar. |
| Apr 11, 2018 | From committee: Do pass. To Consent Calendar. (Ayes 15. Noes 0.) (April 11). |
| Apr 3, 2018 | Re-referred to Com. on APPR. |
| Apr 2, 2018 | Read second time and amended. |
| Mar 22, 2018 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (March 20). |
| Jan 22, 2018 | Referred to Com. on HEALTH. |
| Jan 9, 2018 | From printer. May be heard in committee February 8. |
| Jan 8, 2018 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 13, 2018 | AB 1788 SALAS Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Jul 5, 2018 | Assembly 3rd Reading AB1788 Salas et al. By Galgiani | Senate Floor |
Passed |
|
| Jun 13, 2018 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| Apr 19, 2018 | AB 1788 SALAS Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 11, 2018 | Do pass. To Consent Calendar. | Assembly Standing Committee on Appropriations |
Passed |
|
| Mar 20, 2018 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1788
Author:(Salas and Grayson)
As Amended Ver:June 18, 2018
Majority vote
ASSEMBLY: | 71-0 | (April 19, 2018) | SENATE: | 35-0 | (July 5, 2018) |
Original Committee Reference: HEALTH
SUMMARY: Authorizes the Department of Public Health (DPH) to use laboratory results to confirm a case of Valley Fever with or without clinical criteria.
The Senate amendments sunset the provisions of this bill on January 1, 2024.
FISCAL EFFECT: According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, negligible state costs.
COMMENTS: According to the authors, this bill would improve accuracy, efficiency, and consistency in the reporting and confirmation process for Valley Fever by allowing positive laboratory test data to confirm cases of Valley Fever. There is no vaccine or cure for Valley Fever and it is often misdiagnosed because its symptoms resemble other common illnesses. In California, Valley Fever reporting requires that the disease meets the national case definition, which requires both laboratory data and clinical information. The follow-up needed to collect all the required clinical data is resource intensive and time consuming for county health departments. Due to this case definition, counties have been overwhelmed and many do not have the resources to conduct the clinical follow up, which leads to underreporting or inconsistencies in the reporting process. Arizona has adopted the case definition to allow laboratory confirmation which studies show to be 97% accurate, and allow for enhanced surveillance methods, increased timeliness or reporting, and required minimal resources. The authors conclude that providing local health departments (LHDs) with a consistent, standardized case definition that has been proven in studies to simultaneously increase efficiency, reduce strain on resources, and maintain accuracy will improve the state’s ability to handle the record high, rapidly rising number of Valley Fever cases.
Valley Fever is an infectious disease caused by a fungus, Coccidioides, which is found in arid soil and desert-like regions of California, the southwestern region of the U.S., parts of Mexico, Central America, and South America. Individuals and domestic animals can become infected with Valley Fever through breathing in the microscopic Coccidioides fungus spores. Anyone who lives, works, or visits areas with the contaminated soil is at risk for Valley Fever. The majority of counties in California have reported cases of Valley Fever, but a large portion of Valley Fever cases are found in the California Central Valley. According to DPH, approximately 60% of infected individuals will not present any symptoms. However, for many individuals infected with Valley Fever they will present with flu-like symptoms which last from a few weeks to a few months. Approximately 5-10% of individuals infected will develop severe Valley Fever and may suffer life-long complications. In very rare cases Valley Fever can be fatal. There is no vaccine to prevent infection or cure for those who have been infected, but current research is working towards this goal.
All cases, suspected or confirmed, of Valley Fever are reported to DPH. DPH utilizes the national case definition established by the Council of State and Territorial Epidemiologists and the federal Centers for Disease Control and Protection which requires a case of Valley Fever meet both the laboratory and clinical criteria. Clinical criteria used in confirming Valley Fever includes a physical examination of the patient. Laboratory criteria include a positive laboratory result for Valley Fever. In order to determine whether suspect cases actually meet the surveillance case definition for Valley Fever, LHDs must follow up with health care providers or the patients and collect additional patient clinical information. Valley Fever is a complex disease that can mimic many other common illnesses. Laboratory results help to confirm a case of Valley Fever. However, according to DPH, no single laboratory test can confirm an active case of Valley Fever and clinical information is helpful in determining whether a reported case is active or whether a laboratory test represents an infection acquired in the past.
In 1997, Arizona modified their case definition of Valley Fever to use laboratory results to confirm a case of Valley Fever with or without clinical criteria. Arizona made this modification because of the high number of reported cases, lack of resources to investigate all reported cases, and very high rate of clinical symptoms among laboratory-reported cases. Studies show using laboratory criteria in cases of Valley Fever does increase timeliness and accuracy of reporting in Valley Fever endemic areas. It is important to note, all of Arizona is considered endemic for Valley Fever and annually has the highest number of Valley Fever cases in the nation.
In response to the increase of Valley Fever cases, DPH recently convened a Valley Fever Workgroup (Workgroup). The purpose of the Workgroup is to improve understanding, standardize surveillance, and hold opportunities for communication between DPH and LHDs from endemic areas of Valley Fever. The Workgroup first met in October of 2017, and continues to meet monthly. It has four specific goals: to better understand how each local health jurisdiction is currently conducting surveillance of Valley Fever; develop a plan for systematic and standardized approach to Valley Fever surveillance in California; including the possibility of a revised case definition for disease monitoring that will facilitate more rapid reporting and case confirmation; discuss ways to increase public awareness of Valley Fever with the public and also medical providers; and, determine the need for new Valley Fever educational materials and additional tools for possible Valley Fever outbreaks.
The Valley Fever Americas Foundation (VFAF) writes in support of this bill would reduce underreporting, decrease the burden on LHDs, increase accuracy, and enhance monitoring and surveillance of the disease. VFAF also notes that as cases of Valley Fever continue to rise across California, it is important that policymakers have accurate data in order to address the problem.
The Health Officers association of California (HOAC) writes in opposition that this bill would encourage a modified Valley Fever surveillance case definition, allowing DPH to confirm provisional cases of Valley Fever without meeting clinical criteria. HOAC states that clinical criteria is intended to improve the accuracy of Valley Fever reporting and this bill could actually lead to less precise counts, inflating the numbers by allowing the use of positive laboratory test data alone to confirm cases.
Analysis Prepared by: Monica Montano / HEALTH / (916) 319-2097 FN: 0003733
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 1788
:
SENATE HEALTH COMMITTEE: 8-0, 6/13/18
AYES: Pan, Nguyen, Hernandez, Leyva, Mitchell, Monning, Nielsen, Roth
NO VOTE RECORDED: Newman
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 71-0, 4/19/18 (Consent) - See last page for vote
DIGEST:
This bill permits the Department of Public Health, for the purpose of reports confirming a case of valley fever, to use laboratory criteria for diagnosis, with or without clinical criteria until January 1, 2024.
Existing law:
- Requires the Department of Public Health (DPH) to establish a list of reportable diseases and conditions to be properly reported as required to DPH by local health officers (LHOs). Requires DPH to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made. Permits the list to include both communicable and noncommunicable diseases. Permits the list to be modified at any time by DPH, after consultation with the California Conference of Local Health Officers. [HSC §120130]
- Requires DPH to establish a list of communicable diseases and conditions for which clinical laboratories are required submit a culture or a specimen to the local public health laboratory. Requires the list to set forth the conditions under which the culture and specimen is also required to be submitted to the State Public Health Laboratory. Permits the list to be modified at any time by DPH, in consultation with appropriate local public health stakeholders, including, but not limited to, LHOs and public health laboratory directors. [HSC §120130]
- Requires every health care provider, knowing of or in attendance on a case or suspected case of any reportable diseases or conditions, to report to the LHO for the jurisdiction where the patient resides. Permits any individual having knowledge of a person who is suspected to be suffering from one of the diseases to make such a report to the LHO for the jurisdiction where the patient resides when there is no health care provider in attendance. Defines "health care provider" as a physician and surgeon, a veterinarian, a podiatrist, a nurse practitioner, a physician assistant, a registered nurse, a nurse midwife, a school nurse, an infection control practitioner, a medical examiner, a coroner, or a dentist. [17 CCR §2500, et seq.]
- Requires an administrator of each health facility, clinic, or other setting where more than one health care provider may know of a case, a suspected case or an outbreak of disease within the facility, to establish and be responsible for administrative procedures to assure that reports are made to the LHO. [17 CCR §2500, et seq.]
- Requires each clinical laboratory director, or the laboratory director's designee, an approved public health laboratory, or a veterinary laboratory, to report findings of specified communicable diseases and conditions to the LHO of the local health jurisdiction where the health care provider who first submitted the specimen is located, except for acute HIV infection reporting (which has unique reporting requirements). Requires the laboratory, if the patient residence is unknown, to notify the LHO of the jurisdiction in which the health care provider is located. [17 CCR §2505, et seq.]
This bill permits DPH, for the purpose of reports confirming a case of coccidioidomycosis (also known as valley fever) use laboratory criteria for diagnosis, with or without clinical criteria until January 1, 2024.
Background
- Valley fever. According to the Centers for Disease Control and Prevention (CDC), valley fever is caused by coccidioides, a fungus that lives in soil in the southwestern United States and parts of Mexico, Central America, and South America. Inhaling the airborne fungal spores can cause infection, but is not spread from person to person. Most people who are exposed to the fungus do not get sick, but some people develop flu-like symptoms that may last for weeks to months. In a very small proportion of people who get valley fever, the infection can spread from the lungs to the rest of the body and cause more severe conditions, such as meningitis or even death. While anyone in an endemic area is at risk, those working in occupations involving dirt and dust exposure may be at increased risk of infection. Several groups of people are at higher risk for developing the severe forms of valley fever, including African Americans, Asians, diabetics, and people with weak immune systems, including those with an organ transplant or who have HIV/AIDS.
- California incidence. According to the CDC, between 1998 and 2016 the number of reported valley fever cases in California slowly climbed from 719 in 1998 to a peak in 2011 of 5,697. Those numbers were on the decline until 2016, when the number appeared to creep back up with 5,358 reported cases. Although most cases of valley fever are not associated with outbreaks, outbreaks linked to a common source do occasionally occur, particularly after events that disturb large amounts of soil. Past outbreaks have occurred in military trainees, archeological workers, solar farm workers, and in people exposed to earthquakes, and dust storms. The number of valley fever cases varies from year to year, and by season. Cases can be more common in the late summer and fall. Provisional cases include suspect, probable, and confirmed cases: suspect and probable cases may be confirmed later or excluded as official cases upon further investigation. According to DPH, the counties with the highest annual incidence rates in 2016 included Kern (251.7 per 100,000), Kings (157.3 per 100,000), San Luis Obispo (82.8 per 100,000), Fresno (60.8 per 100,000),Tulare (45.3 per 100,000), Madera (31.5 per 100,000), and San Joaquin (25.3 per 100,000).
- Existing reporting mechanisms. According to DPH’s Web site, its Division of Communicable Disease Control (DCDC) works to promptly identify, prevent and control infectious diseases that pose a threat to public health. DPH works with LHOs to implement infectious disease control at the local level through the 61 legally-appointed physician LHOs in California, one from each of the 58 counties and three cities of Berkeley, Long Beach and Pasadena. DCDC identifies, prevents and controls infectious diseases that pose a threat to public health, including emerging and re-emerging infectious diseases, vaccine-preventable agents, bacterial toxins, bioterrorism, and pandemics. DCDC works with LHOs to identify and monitor reported cases of over 70 reportable diseases, including valley fever. These reportable diseases and conditions are reported by health care providers and laboratories to LHOs, who report this information to DPH. For most counties, local health department staff enter case information into the California Reportable Disease Information Exchange (CalREDIE), which is the statewide electronic disease reporting system. Basic patient identifying information is required for each case of valley fever; a longer Coccidioidomycosis Case Report Form with more information requested is available but is voluntary and not required.
- Reporting valley fever. The California Code of Regulations Title 17 requires that health care providers report cases of valley fever within seven calendar days to the LHO. Laboratories are required to report within one working day after the health care provider has been notified. According to DPH, LHOs may collect additional information from health care providers to determine whether a case meets standard case definitions, and then report cases to DPH. When LHOs enter data into CalREDIE, they initially mark them as “Suspect” if not enough information is available to confirm, and later change the classification to “Confirmed” if additional information shows that the case meets the standard definition. Both DPH and LHOs can review information in CalREDIE. For valley fever, LHOs receive reports of “Suspect” cases from local laboratories and health care providers, with most reports containing only minimal information. For example, valley fever cases reported by laboratories usually contain only the positive laboratory result(s), with no clinical information, such as signs or symptoms of illness. The national surveillance case definition for valley fever requires both laboratory and clinical criteria. For the clinical criteria to be met, the patient must have signs and symptoms consistent with valley fever. In order to determine whether suspect cases actually meet the surveillance case definition, LHOs must follow up with health care providers or the patients and collect additional information. DPH states that because valley fever is a complex disease, it can be difficult to determine whether a positive laboratory result represents a false positive result, a recent infection, or an infection acquired in the past. Collecting additional patient clinical information helps determine whether the patient has valley fever currently or not. Some cases initially reported as “Suspect” are eventually not confirmed as valley fever cases. If the case meets the surveillance case definition of valley fever, it is counted for regular data reports. Currently, Kern and Los Angeles are two counties that report using laboratory criteria only.
Comments
Author’s statement. According to the author, this bill improves accuracy, efficiency and consistency in the reporting and confirmation process for valley fever by allowing positive laboratory test data to confirm cases of valley fever. Valley fever is a dramatically underreported disease. There is no vaccine or cure for valley fever and it is often misdiagnosed because its symptoms resemble other common illnesses. A record total number of cases were reported in 2016 and is expected to be even higher in 2017. However, the rising numbers do not reflect the true extent of valley fever in our state. According to the CDC, an additional 150,000 cases go unreported every year in the United States. In California, valley fever reporting requires that the disease meets both laboratory data and clinical information. The follow up needed to collect all the required clinical data is resource intensive and time consuming for county health departments. Some counties do not have the resources to conduct the clinical follow up, which could lead to underreporting or inconsistencies in the reporting process. Arizona has adopted the case definition to allow laboratory confirmation, which studies showed 97% of cases also met the clinical definition, and allow for enhanced surveillance methods, increased timeliness of reporting, and required minimal resources. The modified case definition will increase efficiency, reduce strain on resources, and maintain accuracy.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
Acton Town Council
Arvin Union School District
California State Association of Electrical Workers
California State Pipe Trades Council
City of Arvin
City of Bakersfield
City of Corcoran
City of Delano
City of Hanford
City of McFarland
City of Wasco
County of Kern
International Brotherhood of Electrical Workers Local 428
Kern Health Systems
Kern Medical
Lamont Elementary School District
The Wonderful Company LLC
Valley Children’s Healthcare
Valley Fever Americas Foundation
Western States Council of Sheet Metal Workers
Health Officers Association of California
ARGUMENTS IN SUPPORT: Supporters write that the follow up needed to collect all the clinical data required to report a case of valley fever is resource intensive and time consuming for counties. Local health departments are currently required to follow up on reported cases of valley fever to collect additional information needed to confirm that the case meets the clinical definition. However, many local health departments do not have the resources necessary to follow up on reported cases, which means that they are not being counted. By allowing positive lab tests to confirm cases of valley fever, it would reduce underreporting, decrease the burden on local health departments, increase accuracy, and enhance monitoring and surveillance of the disease. Supporters further state that as cases of valley fever continue to rise across California, it is important that policymakers have accurate data in order to address the problem.
ARGUMENTS IN OPPOSITION: The Health Officers Association of California (HOAC) writes that positive valley fever lab test results do not necessarily reveal an active infection; the data may be representative of a previously acquired infection, and without meeting clinical criteria (meaning that the patient is presenting symptoms of an infection), positive valley fever lab results are counted as suspected cases. HOAC states that using only a lab test as a case definition is problematic, especially in areas where valley fever is not endemic.
ASSEMBLY FLOOR: 71-0, 4/19/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Eggman, Flora, Fong, Frazier, Friedman, Gallagher, Gipson, Gloria, Gonzalez Fletcher, Gray, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk-Silva, Reyes, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Calderon, Cristina Garcia, Eduardo Garcia, Melendez, Mullin, Quirk, Rodriguez
7/3/18 15:47:01
**** END ****
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: AB 1788
AUTHOR: | Salas | ||
VERSION: | April 2, 2018 | ||
HEARING DATE: | June 13, 2018 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Public health: Valley Fever
SUMMARY:
Permits the Department of Public Health, for the purpose of reports confirming a case of valley fever, to use a laboratory criteria for diagnosis, with or without clinical criteria.
Existing law:
- Requires the Department of Public Health (DPH) to establish a list of reportable diseases and conditions to be properly reported as required to DPH by local health officers (LHOs). Requires DPH to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, reports made. Permits the list to include both communicable and noncommunicable diseases. Permits the list to be modified at any time by DPH, after consultation with the California Conference of Local Health Officers. [HSC §120130]
- Requires DPH to establish a list of communicable diseases and conditions for which clinical laboratories are required submit a culture or a specimen to the local public health laboratory. Requires the list to set forth the conditions under which the culture and specimen is also required to be submitted to the State Public Health Laboratory. Permits the list to be modified at any time by DPH, in consultation with appropriate local public health stakeholders, including, but not limited to, LHOs and public health laboratory directors. [HSC §120130]
- Requires, through regulation, every health care provider, knowing of or in attendance on a case or suspected case of any reportable diseases or conditions, to report to the LHO for the jurisdiction where the patient resides. Permits any individual having knowledge of a person who is suspected to be suffering from one of the diseases to make such a report to the LHO for the jurisdiction where the patient resides when there is no health care provider in attendance. Defines "health care provider" as a physician and surgeon, a veterinarian, a podiatrist, a nurse practitioner, a physician assistant, a registered nurse, a nurse midwife, a school nurse, an infection control practitioner, a medical examiner, a coroner, or a dentist. [17 CCR §2500, et seq.]
- Requires, through regulation, an administrator of each health facility, clinic, or other setting where more than one health care provider may know of a case, a suspected case or an outbreak of disease within the facility, to establish and be responsible for administrative procedures to assure that reports are made to the LHO. [17 CCR §2500, et seq.]
- Requires, through regulation, each clinical laboratory director, or the laboratory director's designee, an approved public health laboratory, or a veterinary laboratory, to report findings of specified communicable diseases and conditions to the LHO of the local health jurisdiction where the health care provider who first submitted the specimen is located, except for acute HIV infection reporting (which has unique reporting requirements). Requires the laboratory, if the patient residence is unknown, to notify the LHO of the jurisdiction in which the health care provider is located. [17 CCR §2505, et seq.]
This bill: Permits DPH, for the purpose of reports confirming a case of coccidioidomycosis (also known as valley fever) use a laboratory criteria for diagnosis, with or without clinical criteria.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, negligible costs.
PRIOR VOTES:
Assembly Floor: | 71 - 0 |
Assembly Appropriations Committee: | 15 - 0 |
Assembly Health Committee: | 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, this bill would improve accuracy, efficiency and consistency in the reporting and confirmation process for valley fever by allowing positive laboratory test data to confirm cases of valley fever. Valley fever is a dramatically underreported disease. There is no vaccine or cure for valley fever and it is often misdiagnosed because its symptoms resemble other common illnesses. A record total number of cases were reported in 2016 and is expected to be even higher in 2017. However, the rising numbers do not reflect the true extent of valley fever in our state. According to the CDC, an additional 150,000 cases go unreported every year in the United States. In California, valley fever reporting requires that the disease meets both laboratory data and clinical information. The follow up needed to collect all the required clinical data is resource intensive and time consuming for county health departments. Some counties do not have the resources to conduct the clinical follow up, which could lead to underreporting or inconsistencies in the reporting process. Arizona has adopted the case definition to allow laboratory confirmation, which studies showed 97% of cases also met the clinical definition, and allow for enhanced surveillance methods, increased timeliness of reporting, and required minimal resources. The modified case definition will increase efficiency, reduce strain on resources, and maintain accuracy.
- Background. According to the CDC, valley fever is caused by coccidioides, a fungus that lives in soil in the southwestern United States and parts of Mexico, Central America, and South America. Inhaling the airborne fungal spores can cause infection, but is not spread from person to person. Most people who are exposed to the fungus do not get sick, but some people develop flu-like symptoms that may last for weeks to months. In a very small proportion of people who get valley fever, the infection can spread from the lungs to the rest of the body and cause more severe conditions, such as meningitis or even death. While anyone in an endemic area is at risk, those working in occupations involving dirt and dust exposure may be at increased risk of infection. Several groups of people are at higher risk for developing the severe forms of valley fever, including African Americans, Asians, diabetics, and people with weak immune systems, including those with an organ transplant or who have HIV/AIDS.
- Endemic areas. The CDC map below shows the approximate areas (called “endemic areas”) where coccidioides is known to live or is suspected to live in the U.S. and Mexico. Much of what is known about where the fungus lives in the southwestern U.S. is based on studies performed in the late 1940s and early 1950s. The map also shows the locations of several outbreaks and locations of valley fever cases acquired outside of the areas identified by skin testing. Coccidioides might also live in similar areas with hot, dry climates that are not shaded on the map.
- California incidence. According to the CDC, between 1998 and 2016 the number of reported valley fever cases in California slowly climbed from 719 in 1998 to a peak in 2011 of 5,697. Those numbers were on the decline until 2016, when the number appeared to creep back up with 5,358 reported cases. Although most cases of valley fever are not associated with outbreaks, outbreaks linked to a common source do occasionally occur, particularly after events that disturb large amounts of soil. Past outbreaks have occurred in military trainees, archeological workers, solar farm workers, and in people exposed to earthquakes, and dust storms. The number of valley fever cases varies from year to year, and by season. Cases can be more common in the late summer and fall. Provisional cases include suspect, probable, and confirmed cases: suspect and probable cases may be confirmed later or excluded as official cases upon further investigation. According to DPH, the counties with the highest annual incidence rates in 2016 included Kern (251.7 per 100,000), Kings (157.3 per 100,000), San Luis Obispo (82.8 per 100,000), Fresno (60.8 per 100,000),Tulare (45.3 per 100,000), Madera (31.5 per 100,000), and San Joaquin (25.3 per 100,000).
- Vaccine. Valley fever research has been going on since the 1930s and 40s, with not much progress towards a vaccine. According to a report published in October 2012 by the Reporting On Health collaborative (an initiative of The California Endowment Health Journalism Fellowships at the University of Southern California’s Annenberg School for Communication and Journalism), when a valley fever vaccine was evaluated in the late 1970s and early 1980s, and proved to be effective in mice and monkeys, hundreds of people signed up for the human clinical (Phase III) trials. However, patients complained of very sore arms and swelling at the injection site even at low doses. The shot was so painful people dropped out of the trial, and ultimately the vaccine did not show conclusive protection. In 1997, a Bakersfield-based committee worked with California State University, Bakersfield to select five U.S. scientists to develop a new vaccine with funding from the California HealthCare Foundation (CHCF) and the State of California. The project was launched with a $1.5 million grant from CHCF, $700,000 in state general funds, and a contribution of more than $100,000 from rotary clubs. With further contributions over the next decade from CHCF, the federal government, the state, the county of Kern and nonprofit groups, total funding reached about $16 million. However, funding dried up and the research stalled. DPH reports that it last received funding for valley fever in 2009-10 when $1 million in state funding was appropriated for valley fever vaccine development. Most of that funding was provided to an academic advisory group to coordinate vaccine research grants because DPH lacks technical expertise and capacity to monitor valley fever vaccine development projects. That funding was exhausted in 2010 and DPH is no longer involved in any research for a valley fever vaccine.
- Existing reporting mechanisms. According to DPH’s website, its Division of Communicable Disease Control (DCDC) works to promptly identify, prevent and control infectious diseases that pose a threat to public health. DPH works with LHOs to implement infectious disease control at the local level through the 61 legally-appointed physician LHOs in California, one from each of the 58 counties and three cities of Berkeley, Long Beach and Pasadena. DCDC identifies, prevents and controls infectious diseases that pose a threat to public health, including emerging and re-emerging infectious diseases, vaccine-preventable agents, bacterial toxins, bioterrorism, and pandemics. DCDC works with LHOs to identify and monitor reported cases of over 70 reportable diseases, including valley fever. These reportable diseases and conditions are reported by health care providers and laboratories to LHOs, who report this information to DPH. For most counties, local health department staff enter case information into the California Reportable Disease Information Exchange (CalREDIE), which is the statewide electronic disease reporting system. Basic patient identifying information is required for each case of valley fever; a longer Coccidioidomycosis Case Report Form with more information requested is available but is voluntary and not required.
- Reporting valley fever. The California Code of Regulations (CCR) Title 17 requires that health care providers report cases of valley fever within 7 calendar days to the LHO. Laboratories are required to report within one working day after the health care provider has been notified. According to DPH, LHOs may collect additional information from health care providers to determine whether a case meets standard case definitions, and then report cases to DPH. When LHOs enter data into CalREDIE, they initially mark them as “Suspect” if not enough information is available to confirm, and later change the classification to “Confirmed” if additional information shows that the case meets the standard definition. Both DPH and LHOs can review information in CalREDIE. For valley fever, LHOs receive reports of “Suspect” cases from local laboratories and health care providers, with most reports containing only minimal information. For example, valley fever cases reported by laboratories usually contain only the positive laboratory result(s), with no clinical information, such as signs or symptoms of illness. The national surveillance case definition for valley fever requires both laboratory and clinical criteria. For the clinical criteria to be met, the patient must have signs and symptoms consistent with valley fever. In order to determine whether suspect cases actually meet the surveillance case definition, LHOs must follow up with health care providers or the patients and collect additional information. DPH states that because valley fever is a complex disease, it can be difficult to determine whether a positive laboratory result represents a false positive result, a recent infection, or an infection acquired in the past. Collecting additional patient clinical information helps determine whether the patient has valley fever currently or not. Some cases initially reported as “Suspect” are eventually not confirmed as valley fever cases. If the case meets the surveillance case definition of valley fever, it is counted for regular data reports. Currently, Kern and Los Angeles are two counties that report using laboratory criteria only.
- Related legislation. AB 1787 (Salas) place new reporting requirements on DPH related to valley fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by the state’s electronic data system by April 15 of each year; reporting to LHOs about any removal of discrepant data; and including an explanation for likely data changes between initial and final publication of data, and an explanation for discrepancies between data reported by an LHO and data reported by DPH. AB 1787 is set to be heard on June 13, 2018 in this Committee.
AB 1789 (Salas) requires the Occupational Safety and Health Standards Board to adopt valley fever standards for state public works projects, as specified. AB 1789 was held on the Assembly Committee of Appropriations suspense file.
AB 1790 (Salas) establishes the Valley Fever Education, Early Diagnosis, and Treatment Act to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever. AB 1790 is set to be heard on June 13, 2018 in this Committee.
- Prior legislation. AB 1279 (Salas) of 2017 would have required DPH to develop and implement public outreach programs to educate the public about valley fever. AB 1279 was vetoed by the Governor, who stated, “The department already provides fact sheets, brochures, posters and other educational materials to raise awareness of this disease. Expanding this program would necessitate additional resources which should be considered along with other funding requests as part of the budget process.”
SB 115 (Fuller of 2015) would have appropriated $1 million from the General Fund to DPH for purposes of valley fever vaccine research. SB 115 was held on the Senate Committee of Appropriations suspense file.
SB 1044 (Fuller of 2014), AB 1955 (Ashburn of 2002), SB 1027 (Ashburn of 2003) and SB 492 (Ashburn of 2005) were substantially similar to SB 115. SB 1044 was referred to Banking and Finance but never acted upon. AB 1955, SB 1027 and SB 492 were held on the Assembly Committee of Appropriations suspense file.
- Support. Supporters write that the follow up needed to collect all the clinical data required to report a case of valley fever is resource intensive and time consuming for counties. Local health departments are currently required to follow up on reported cases of valley fever to collect additional information needed to confirm that the case meets the clinical definition. However, many local health departments do not have the resources necessary to follow up on reported cases, which means that they are not being counted. By allowing positive lab tests to confirm cases of valley fever, it would reduce underreporting, decrease the burden on local health departments, increase accuracy, and enhance monitoring and surveillance of the disease. Supporters further state that as cases of valley fever continue to rise across California, it is important that policymakers have accurate data in order to address the problem.
- Opposition. The Health Officers Association of California (HOAC) writes that positive valley fever lab test results do not necessarily reveal an active infection; the data may be representative of a previously acquired infection, and without meeting clinical criteria (meaning that the patient is presenting symptoms of an infection), positive valley fever lab results are counted as suspected cases. HOAC states that using only a lab test as a case definition is problematic, especially in areas where valley fever is not endemic.
- Policy comment. DPH already has the authority to determine how LHOs report cases of valley fever, or any other reportable disease. DPH states that it is considering, through a working group comprised of state and local health officials and valley fever experts, whether LHOs can use only laboratory criteria to confirm cases. Additionally, DPH states that whether this bill passes has no effect on this consideration, given that this bill is permissive and it already has the legal authority to determine how diseases are reported. Should the working group determine that only laboratory-based reported should be implemented, DPH will do so.
SUPPORT AND OPPOSITION:
Support: Acton Town Council
Arvin Union School District
California State Association of Electrical Workers
California State Pipe Trades Council
City of Arvin
City of Bakersfield
City of Corcoran
City of Delano
City of Hanford
City of McFarland
City of Wasco
County of Kern
International Brotherhood of Electrical Workers Local 428
Kern Health Systems
Kern Medical
Lamont Elementary School District
The Wonderful Company LLC
Valley Children’s Healthcare
Valley Fever Americas Foundation
Western States Council of Sheet Metal Workers
Oppose: Health Officers Association of California
-- END --
Date of Hearing: April 11, 2018
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez Fletcher, Chair
ABPCA Bill Id:AB 1788
Author:(Salas) – As Amended Ver:April 2, 2018
Policy Committee: | Health | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill allows the California Department of Public Health, for the purpose of reports confirming a case of coccidioidomycosis (Valley Fever), to use laboratory criteria for diagnosis with or without clinical criteria.
FISCAL EFFECT:
Negligible.
COMMENTS:
- Purpose. The author asserts relying on positive laboratory test data to confirm cases of Valley Fever will reduce underreporting and improve accuracy.
- Background. Valley Fever is a flu-like infection caused by a fungus found in the American southwest and northern Mexico. Most cases in California are in the southern Central Valley and Central Coast. People can get Valley Fever by breathing in microscopic fungal spores from the air, although most people who breathe in the spores don’t get sick. Most who do get sick recover on their own within weeks to months, but some people will need antifungal medication and certain populations are at risk of severe illness.
State public health regulations require each local health officer to report at least weekly the number of cases for each condition specified on the "reportable conditions" list maintained by CDPH. This list includes coccidioidomycosis (Valley Fever). A case is considered "suspected" until it's confirmed. Confirmed cases meet the Centers for Disease Control and Prevention (CDC) case definition, whereby both clinical criteria and a positive laboratory test must be present. The inclusion of clinical criteria is necessary because the fungus can be present in the body and result in a positive laboratory test result even if a person does not have active illness. This bill would authorize the department to use a laboratory test result as the sole basis to confirm a case.
- Support and Opposition. This bill is supported by Valley Fever Americas Foundation and local government entities, among others. The Health Officers Association of California (HOAC), comprised of local health officers who oversee disease control, oppose this bill. HOAC indicates this bill is premature given ongoing Valley Fever Workgroup discussions and believes it may result in inaccurate, overinflated case counts.
- Related Legislation. AB 1787 (Salas), also being heard today, establishes an annual statutory reporting deadline for Valley Fever.
AB 1790 (Salas), pending in the Assembly Business and Professions Committee, requires clinics and hospitals to develop and implement policies and procedures, including education and training, related to Valley Fever prevention, diagnosis, and treatment.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: March 20, 2018
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1788
Author:(Salas and Fong) – As Introduced Ver:January 8, 2018
SUBJECT: Public health: Valley Fever.
SUMMARY: Authorizes the Department of Public Health (DPH) to use laboratory results to confirm a case of Valley Fever with or without clinical criteria.
EXISTING LAW:
- Requires DPH to establish a list of reportable communicable and noncommunicable diseases and conditions and specify the timeliness requirement for the reporting of each disease and condition.
- Requires every health care provider, knowing of or in attendance on a case or suspected case of any of diseases or conditions as specified, to report to the local health officer (LHO) for the jurisdiction where the patient resides.
- Requires an administrator of each health facility, clinic, or other setting where more than one health care provider may know of a case, a suspected case or an outbreak of disease within the facility to establish and be responsible for administrative procedures to assure that reports are made to the local health officer.
- Requires LHOs to report cases of identified diseases to DPH.
- Requires an approved clinical public health laboratory to report findings of reportable diseases to the LHO for the local health jurisdiction where the patient resides.
- Requires the case of a disease or condition follows the most recent communicable disease surveillance cases definition established by the Centers for Disease Control and Prevention (CDC).
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the authors, this bill would improve accuracy, efficiency, and consistency in the reporting and confirmation process for Valley Fever by allowing positive laboratory test data to confirm cases of Valley Fever. Valley Fever is a dramatically underreported disease that can be debilitating and even fatal. There is no vaccine or cure for Valley Fever and it is often misdiagnosed because its symptoms resemble other common illnesses. A record high of 5,372 cases were reported in 2016 and the provisional numbers for 2017 are even higher with 7,471 cases initially reported by DPH, a 39% increase over the state’s all-time high in 2016. However, these rapidly rising numbers do not reflect the true extent of Valley Fever in our state. In California, Valley Fever reporting requires that the disease meets the national case definition, which requires both laboratory data and clinical information. The follow-up needed to collect all the required clinical data is resource intensive and time consuming for county health departments. Due to this case definition, counties have been overwhelmed and many do not have the resources to conduct the clinical follow up, which leads to underreporting or inconsistencies in the reporting process. Arizona has adopted the case definition to allow laboratory confirmation which studies show to be 97% accurate, and allow for enhanced surveillance methods, increased timeliness or reporting, and required minimal resources. The authors conclude that providing local health departments (LHDs) with a consistent, standardized case definition that has been proven in studies to simultaneously increase efficiency, reduce strain on resources, and maintain accuracy will improve the state’s ability to handle the record high, rapidly rising number of Valley Fever cases.
- BACKGROUND.
- Valley Fever. Valley Fever is an infectious disease caused by a fungus, Coccidioides, which is found in arid soil and desert-like regions of California, the southwestern region of the U.S., parts of Mexico, Central America, and South America. Individuals and domestic animals can become infected with Valley Fever through breathing in the microscopic Coccidioides fungus spores. Anyone who lives, works, or visits areas with the contaminated soil is at risk for Valley Fever. It is important to note that individuals and/or animals infected with Valley Fever are not contagious. The majority of counties in California have reported cases of Valley Fever, but a large portion of Valley Fever cases are found in the California Central Valley. According to DPH, approximately 60% of infected individuals will not present any symptoms. However, for many individuals infected with Valley Fever they will present with flu-like symptoms which last from a few weeks to a few months. Approximately 5-10% of individuals infected will develop severe Valley Fever and may suffer life-long complications. In very rare cases Valley Fever can be fatal.
There is no vaccine to prevent infection or cure for those who have been infected, but current research is working towards this goal. State funding for the Valley Fever Vaccine Project began with a budget augmentation request by then-Assemblymember Ashburn for $700,000 in 1997-198. In 2009, the Budget Act included an ongoing appropriation of $1 million to continue research activities earmarked toward the development of a vaccine. Funding was subsequently discontinued in 2010. In 2015, SB 115 (Fuller) was introduced which would have appropriated $1 million from the General Fund to DPH for Valley Fever vaccine research. SB 115 was held in the Assembly Appropriations Committee. Numerous similar allocation requests between 2002 and 2014 were held in the Assembly Appropriations Committee. Currently, Assemblymembers Salas and Fong have budget proposals regarding appropriations for Valley Fever vaccine research and a Valley Fever public awareness campaign.
- Case Confirmation. All cases, suspected or confirmed, of Valley Fever are reported to DPH. Suspected cases are used in DPH’s Provisional Monthly Report that is updated and posted monthly. There are cases of Valley Fever that are initially reported as suspected, but are eventually not confirmed cases of Valley Fever. DPH publishes an annual case report using only confirmed cases of Valley Fever. DPH utilizes the national case definition established by the Council of State and Territorial Epidemiologists and the CDC which requires a case of Valley Fever meet both the laboratory and clinical criteria. Clinical criteria used in confirming Valley Fever includes a physical examination of the patient and the presentations of symptoms, such as influenza-like symptoms or pneumonia-like symptoms. Laboratory criteria include a positive laboratory result for Valley Fever using one of many types of laboratory tests. If the case does not meet the definition of Valley Fever, then it is not included in annual case counts.
- Reporting Process. In order to determine whether suspect cases actually meet the surveillance case definition for Valley Fever, LHDs must follow up with health care providers or the patients and collect additional patient clinical information. Valley Fever is a complex disease that can mimic many other common illnesses. Laboratory results help to confirm a case of Valley Fever. However, according to DPH, no single laboratory test can confirm an active case of Valley Fever and clinical information is helpful in determining whether a reported case is active or whether a laboratory test represents an infection acquired in the past.
- Case Definition Change. In 1997, Arizona modified their case definition of Valley Fever to use laboratory results to confirm a case of Valley Fever with or without clinical criteria. Arizona made this modification because of the high number of reported cases, lack of resources to investigate all reported cases, and very high rate of clinical symptoms among laboratory-reported cases. Studies show using laboratory criteria in cases of Valley Fever does increase timeliness and accuracy of reporting in Valley Fever endemic areas. It is important to note, all of Arizona is considered endemic for Valley Fever and annually has the highest number of Valley Fever cases in the nation.
- Valley Fever Workgroup. In response to the increase of Valley Fever cases, DPH recently convened a Valley Fever Workgroup (Workgroup). The purpose of the Workgroup is to improve understanding, standardize surveillance, and hold opportunities for communication between DPH and LHDs from endemic areas of Valley Fever. The Workgroup first met in October of 2017, and continues to meet monthly. It has four specific goals:
- To better understand how each local health jurisdiction is currently conducting surveillance of Valley Fever;
- Develop a plan for systematic and standardized approach to Valley Fever surveillance in California; including the possibility of a revised case definition for disease monitoring that will facilitate more rapid reporting and case confirmation;
- Discuss ways to increase public awareness of Valley Fever with the public and also medical providers; and,
- Determine the need for new Valley Fever educational materials and additional tools for possible Valley Fever outbreaks.
- To better understand how each local health jurisdiction is currently conducting surveillance of Valley Fever;
- SUPPORT. The Valley Fever Americas Foundation (VFAF) states this bill would reduce underreporting, decrease the burden on LHDs, increase accuracy, and enhance monitoring and surveillance of the disease. VFAF also notes that as cases of Valley Fever continue to rise across California, it is important that policymakers have accurate data in order to address the problem.
- RELATED LEGISLATION.
- AB 1787 (Salas and Fong) requires DPH to establish an annual deadline beginning on March 1, 2019, for LHOs to report all cases of Valley Fever to DPH. AB 1787 is pending in the Assembly Health Committee.
- AB 1789 (Salas and Fong) requires the Occupational Safety and Health Standards Board to adopt occupational safety and health standard for state public work projects to prevent Valley Fever. AB 1789 passed 6-0 in the Assembly Labor and Employment Committee and is pending in the Assembly Appropriations Committee.
- AB 1790 (Salas and Fong) requires mandatory training for physicians and surgeons on preventing, diagnosing, and treating Valley Fever. AB 1790 is pending in the Assembly Business and Professions Committee.
- AB 1880 (Fong and Salas) requires DPH to collect data on Valley Fever cases on or before April 1st of each year and would require DPH to report to LHOs regarding report changes in Valley Fever cases. AB 1880 is pending in the Assembly Health Committee.
- AB 1881 (Fong and Salas) requires DPH to develop standardized methodology for Valley Fever laboratory tests. AB 1881 is pending in the Assembly Health Committee.
- PREVIOUS LEGISLATION. AB 1279 (Salas) of 2017 would have required DPH to develop and implement a public outreach program to educate individuals about Valley Fever. AB 1279 was vetoed by the Governor, who stated:
“I am returning Assembly Bill 1279 without my signature.
This bill requires the Department of Public Health to develop outreach programs to educate the public about Valley Fever.
The department already provides fact sheets, brochures, posters, and other educational materials to raise awareness of this disease. Expanding this program would necessitate additional resources which should be considered along with other funding requests as part of the budget process.”
- POLICY COMMENT. One of the goals of the Workgroup is to develop a plan for a systematic and standardized approach to Valley Fever surveillance in California. This goal includes a determination of revising the case definition of Valley Fever. Changing the case definition before the Workgroup has the opportunity to determine the case definition may be premature.
REGISTERED SUPPORT / OPPOSITION:
Support
Acton Town Council
Bakersfield City Council
City of Hanford
International Brotherhood of Electrical Workers Local 428
Kern Medical
Valley Fever Americas Foundation
Wonderful Company LLC
Opposition
None on file.
Analysis Prepared by: Monica Montano / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Health
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):